[HTML][HTML] Programmed death-ligand 1 expression and response to the anti–programmed death 1 antibody Pembrolizumab in melanoma
AI Daud, JD Wolchok, C Robert, WJ Hwu… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2016•ncbi.nlm.nih.gov
Purpose Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker
for response and outcome after treatment with anti–programmed death 1 (PD-1). This study
explored the relationship between anti–PD-1 activity and PD-L1 expression in patients with
advanced melanoma who were treated with pembrolizumab in the phase Ib KEYNOTE-001
study (clinical trial information:
for response and outcome after treatment with anti–programmed death 1 (PD-1). This study
explored the relationship between anti–PD-1 activity and PD-L1 expression in patients with
advanced melanoma who were treated with pembrolizumab in the phase Ib KEYNOTE-001
study (clinical trial information:
Abstract
Purpose
Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for response and outcome after treatment with anti–programmed death 1 (PD-1). This study explored the relationship between anti–PD-1 activity and PD-L1 expression in patients with advanced melanoma who were treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information:
ncbi.nlm.nih.gov
